Novel immune assay for quantification of plasma protective capacity against oxidized phospholipids. (August 2016)

• Record Type: Journal Article
• Authors: Bochkov, Valery; Schoenenberger, Andreas W; Oskolkova, Olga; Toth, Ursula; Stöckl, Johannes; Majdic, Otto; Daci, Armond; Resink, Thérèse J; Erne, Paul; Philippova, Maria
• Is Part Of: Biomarkers in medicine. Volume 10:Number 8(2016)
• Page Start: 797
• Page End: 810
• Publication Date: 2016-08
• Subjects: anti-oxidized phospholipid antibodies -- anti-oxidized phospholipid defense -- biomarker potential -- cardiovascular disease -- ELISA -- oxidized phospholipids; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2016-0096
• Languages: English
• ISSNs: 1752-0363

Abstract

Aim: Oxidized phospholipids (OxPL) are the major pathogenic component of oxidized low-density lipoproteins (OxLDL). Endogenous anti-OxPL activity, defined as the ability to neutralize adverse effects of oxidized lipids, may have biomarker potential.Methods & results: Using two anti-OxPL monoclonal antibodies (commercial mAB-E06 and custom mAB-509) we developed a novel ELISA that measures the global capacity of plasma to inactivate OxPL. Preincubation of OxLDL with plasma inhibits its binding of anti-OxPL mABs. This phenomenon ('masking') reflects anti-OxPL plasma activity. A pilot clinical application of the assay revealed reduced anti-OxPL activity in hypertension, coronary artery disease, acute coronary syndrome and diabetes.Conclusion: Inadequate anti-OxPL protection may contribute to cardiovascular disease and have biomarker potential in conditions associated with abnormal lipid peroxidation.